Protein tyrosine phosphatases (PTPs) play key roles in regulating tyrosine phosphorylation levels in cells. Since the discovery of PTP1B as a major drug target for diabetes and obesity, PTPs have emerged as a new and promising class of signaling targets for drug development in a variety of therapeutic areas. The routine use of generic substrate 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) in our hands led to the discovery of very similar and often not very selective molecules. Therefore, to increase the chances to discover novel chemical scaffolds, a side-by-side comparison between the DiFMUP assay and a chipbased mobility shift assay with a specific phosphopeptide was performed, on 1 PTP, using a focused set of compounds. Assay robustness and sensitivity were comparable for both the DiFMUP and mobility shift assays. The off-chip mobility shift assay required a longer development time because of identification, synthesis, and characterization of a specific peptide, and its cost per point was higher. However, although most potent scaffolds found with the DiFMUP assay were confirmed in the mobility shift format, the off-chip mobility shift assay led to the identification of previously unidentified chemical scaffolds with improved druglike properties. (Journal of Biomolecular Screening 2006:996-1004 
INTRODUCTION

P
HOSPHATASES ARE ENZYMES that catalyze the removal of phosphate groups from proteins, lipids, or carbohydrates. Whereas in humans, more than 500 kinases have been identified, 1 the human protein tyrosine phosphatase (PTP) family comprises only 107 genes. 2 With an increasing body of evidence that these enzymes along with kinases are major actors in regulating many intracellular processes involved in diseases, PTPs are rapidly becoming prime targets for the pharmaceutical industry. Notably, following the report of the phenotype of PTP1B knockout mice, 3, 4 which suggested that PTP1B regulates insulin receptor signaling, this phosphatase emerged as a major novel drug target for the treatment of diabetes, with 2 drugs already tested in the clinic. 5 Moreover, several other phosphatases are targeted for drug development. [6] [7] [8] For screening PTPs, one can choose as a substrate either a generic small molecule or a more specific peptide. Of a nonexhaustive list of 40 recently published articles reporting inhibitors for the enzymatic activity of PTP 1B, 26 (65%) reported para-nitrophenyl phosphate (pNPP), 6 (15%) reported fluorescein diphosphate (FDP), and only 2 articles (5%) reported the use of 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) as generic substrates, whereas another 6 (15%) mentioned the use of malachite green together with a specific phosphopeptide.
The most popular generic assay is based on the hydrolysis of colorless pNPP to yellow p-nitrophenol, and the activity of the enzyme is measured by light absorbance. This method, though cheap and robust, suffers from a major drawback-namely, the K m value of phosphatases for pNPP is high, typically in the millimolar range, leading to a low sensitivity to competitive inhibitors at such high concentrations of substrate. More recently, quenched fluorescent generic substrates such as FDP and DiFMUP were designed, which, upon dephosphorylation, turn into a fluorogenic product. 9, 10 In this case, the readout of the assay is fluorescence intensity. K m values for these substrates lie in the micromolar range, and the high signal ratio between substrate and product allows the set up of assays at low substrate concentrations. As a consequence, the sensitivity of the assay toward inhibitors is improved. However, the limitations of these generic substrates are the fact that they are small molecules as compared to the physiological protein substrates and that they are only mimicking a phosphotyrosine moiety. Therefore, it is of concern that results obtained with inhibitors against generic substrates might not be readily extrapolated to the native substrates.
The alternate main option for screening phosphatases is to use a more specific phosphopeptidic substrate and measure its dephosphorylation. For instance, the amount of free phosphate formed upon substrate dephosphorylation can be quantified with malachite green. 11 As this method, though inexpensive, is not very sensitive and prone to interference with contaminants such as free phosphate, alternative techniques were recently developed, based on fluorochrome-labeled phosphopeptides. Readouts can be fluorescence polarization (FP) or fluorescence intensity. In the FP methods, the rotation of a fluorescent phosphopeptide substrate is slowed by interactions with a high-molecular-weight phosphate-binding group, either an antiphosphotyrosine antibody or a trivalent metal coordination complex coupled to a nanoparticle (IMAP; Molecular Devices Corporation, Sunnyvale, CA). Therefore, the polarization signal of the stabilized phosphopeptide substrate is high and decreases upon phosphatase action. Another method is based on the quenching of a fluorescent peptide substrate upon binding of the phosphate group by an iron ion coupled to a quencher (IQ Technology; Pierce, Carlsbad, CA); dephosphorylation of the substrate results in an increase in fluorescence intensity. A competing technology is based on an internally quenched fluorogenic phosphopeptide: Upon phosphatase action, the peptide can be cleaved by chymotrypsin, 12 releasing a fluorogenic peptide fragment. Mobility shift assay (Caliper Life Sciences, Hopkinton, MA), a nanofluidics-based technology, involves electrophoretic separation of the phosphorylated (substrate) and dephosphorylated (product) forms of a fluorescent peptide on a microchip. The parameter measured is fluorescence intensity of the peaks. Reactions can be run on chip with the dephosphorylation reaction taking place in a reaction chamber on the chip, or off chip with the reaction taking place in a microplate well and the microchip being used as a separation device between substrate and product. This technology was successfully implemented in house for kinases, 13 and its use with phosphatases using DiFMUP as a substrate was reported.
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MATERIAL AND METHODS
Materials
Unless otherwise stated, chemicals were purchased from Sigma-Fluka (St. Louis, MO). DiFMUP was from Molecular Probes/Invitrogen (Carlsbad, CA). N-terminally fluoresceinlabeled phosphopeptide (17 amino acids, net charge -2) was purchased from Jerini (Berlin, Germany). Plates with 384 wells were from Corning (Corning, NY). Reference phosphatase inhibitor ((2S)-2-[4′-(2-benzyl-benzofuran-3-yl)-biphenyl-4-yloxy]-3-phenyl-propionic acid (compound A)) was synthesized according to the literature. 15 The phosphatase studied was cloned, expressed in Escherichia coli, and purified in house.
DiFMUP assay
In a 384-well plate, 5 µl of compound at 100 µM in 50% DMSO was incubated with 20 µl of enzyme (10 ng/ml final concentration) and 25 µl of DiFMUP (3 µM final concentration). These reagents were diluted in reaction buffer (20 mM Tris HCl, pH 7.5, 0.01% Igepal CA-630, 0.1 mM EDTA, 1% DMSO, 1 mM DTT). After a 40-min incubation at room temperature, fluorescence intensity (FI) was measured on a Fusion instrument (Perkin-Elmer Life Sciences, Boston, MA). Low controls were performed in the absence of enzyme (columns 1 and 2, A-H, and 24), whereas the high controls were performed in the presence of enzyme and the absence of compounds (columns 1 and 2, I-P). The percentage of inhibition was calculated according to the formula: % inhibition = 100 × (1-(FI compound -FI low control )/(FI high control -FI low control )).
Mobility shift assay
Assays were performed in 384-well plates. Twenty microliters of fluorescein-labeled peptide substrate at 2 µM in reaction buffer, corresponding to 1 µM peptide final, was added to 10 µl of compounds at 40 µM, 20% DMSO, in reaction buffer (final concentration: 10 µM, 5% DMSO). Reaction was started by addition of 10 µl of the enzyme at a concentration of 9 ng/ml in the reaction buffer, corresponding to a final concentration of 2.25 ng/ml ( Table 1) .
After 1 h of incubation, 40 µl of termination buffer was added (reaction buffer containing 0.2% coating-3 reagent (Caliper Life Sciences, Hopkinton, MA) and 30 µM vanadate). Aliquots from each well were sipped by a 12-sipper chip model (760137-0372R) on an HTS 250 Drug Discovery System instrument (Caliper Life Sciences, Hopkinton, MA) for electrophoretic separation of substrate and product peaks under a pressure of -1.6 psi and a voltage of -400∆V and measurement of the fluorescence intensity of the peaks. For assay development individual parameters such as enzyme or substrate concentration, incubation time varied in function of the experiment. The relative peak heights of substrate and product were measured and ratioed using HTS Well Analyzer Software 4.1 from the manufacturer. The ratio (r) was defined as the heights of the product peak divided by the sum of the peak heights of product and substrate. The low controls corresponded to the absence of enzyme in columns 1 and 2 (A-H) and 24, and the high controls corresponded to the absence of compounds in columns 1 and 2 (I-P). Percentage of inhibition was calculated relative to high and low controls as % inhibition = 100 × (1-(r-r low control )/(r high control -r low control )).
Data treatment, assay performance, and descriptors
K m values were calculated using Prism software (Graphpad Software Inc., San Diego, CA). Screening data were treated with the Activity Base software (IDBS, Guildford, UK) and visualized using Spotfire Decision Site 7.1 software (Spotfire, Goeteborg, Sweden). To evaluate the quality of assays, performance was assessed by calculating the Z′ factor value using the following equation: Z′ = 1 -((3SD of high control) + (3SD of low control))/⏐(mean of high control -mean of low control)⏐. 16 For all compounds (parent form), simple descriptorsnamely, the molecular mass (weight), lipophilicity (logP), numbers of hydrogen-bond acceptors and donors, number of rotatable bonds, and the topological polar surface area-were calculated using Molecular Operating Environment software (version 2005.06; Chemical Computing Group Inc., Montreal, Quebec, Canada).
RESULTS AND DISCUSSION
Characterization of the enzyme in the DiFMUP assay
Kinetic parameters of the enzyme were characterized using the generic fluorigenic substrate DiFMUP for the assays, and a K m value of 2.5 µM was determined in kinetic mode, plotting initial velocity versus substrate concentration (Fig. 1) . Identical values were obtained in the presence or the absence of 5% DMSO plus Igepal (data not shown). Fluorescent product coumarin was used to build calibration curves, allowing for the calculation of a specific activity of 125 pmol/ng enzyme/min and a K cat value of 7500/min -1 (data not shown). This high specific activity was comparable to other tyrosine phosphatases previously studied.
Setting up a DiFMUP-based screen
The effect of DMSO on enzyme activity was evaluated, and a detrimental effect was observed at concentrations greater than 2.5%. However, detergent Igepal was found to revert this DMSO effect (data not shown). Therefore, assays were routinely performed in 5% DMSO in the presence of 0.01% Igepal. Moreover, the presence of detergents in assays has been shown to limit the interference of promiscuous binders and aggregating compounds, 17 diminishing the false-positive rate. To evaluate the sensitivity of the assay, the potency of reference compounds was determined, namely, the generic PTP inhibitor vanadate and phosphatase inhibitor ((2S)-2-[4′-(2-benzyl-benzofuran-3-yl)-biphenyl-4-yloxy]-3-phenyl-propionic acid (compound A)). IC 50 values of 0.46 and 4.8 µM were determined for vanadate and compound A, respectively (Fig. 2) . These values are in the range of those obtained in house for previously studied tyrosine phosphatases (data not shown). The next step was to evaluate the robustness of the assay. A run of ten 384-well plates was processed alongside the high-throughput screening (HTS) protocol, and a Z′ factor value of 0.68 was obtained, corresponding to an assay of good quality.
Screening in DiFMUP format
A focused set of 12 403 compounds was tested at a concentration of 10 µM in duplicate, in a 384-well plate format, corresponding to 16 individual runs. Within individual runs, the standard deviation of the high controls (enzyme in the presence of vehicle) ranged from 7% to 18%, whereas the standard deviation of the low controls (no enzyme) ranged from 0.1% to 4.5% (Fig. 3A) . Considering the complete screen, the standard deviation of the high controls was 8.9%, whereas the standard deviation of the low controls was only 0.5% (Fig. 3B) . Therefore, setting a threshold of activity for positives at 3 SD from the high control (or 27% inhibition) translated into 709 positives or a hit rate of 5.7%. As seen in Figure 4A , the signal-to-background ratio fluctuated considerably from 27 to 280 between runs. This could be due to a limited stability of either the enzyme or the DiFMUP substrate in DMSO. Actually, most of the fluctuation could be linked to the instability of a new batch of DiFMUP, as the background of freshly dissolved substrate was rapidly increasing from one day to the other and even within a day. Enzyme activity, however, was stable as measurements were performed at a fixed gain of the photomultiplier, and the fluorescence intensity of the high controls was stable, corresponding to a substrate conversion rate of 20% as estimated from our calibration experiments with coumarin (data not shown). However, the impact of this fluctuation in signal-to-noise ratio on the assay robustness was negligible (Fig. 4A) . In terms of robustness, the assay was good, with values for Z′ factors ranging between 0.4 and 0.9, with a mean value of 0.75. Moreover, the correlation between duplicates (n1 and n2) obtained in 2 independent runs was fair (Fig. 4B) and comparable to those obtained previously with other phosphatases (data not shown).
The high number of positives obtained in the screen is linked to the fact that a focused phosphatase library was screened. Interestingly, interference of fluorescent compounds in the screen appeared to be low. A fluorescent compound would induce an increase in fluorescent intensity and therefore would appear as an activator of the enzyme. As seen in Figure  4B , however, there are very few compounds displaying more than 27% activation (appearing as lower than -27% inhibition on the graph).
Setting up a mobility shift assay
A peptide suitable as a substrate for the phosphatase studied was identified using the SPOT technique. 18, 19 An array of phosphorylated peptides was synthesized on membranes, incubated in the presence of the studied phosphatase, and the remaining phosphoTyr content was estimated by chemoluminescence after immunolabeling with an antiphosphoTyr antibody as described (data not shown). Subsequently, the best peptide substrate was ordered as fluorescein labeled. The apparent K m value for the labeled peptide was determined to be 2.2 µM in the mobility shift assay (Fig. 5) . A comparable value, namely, 1.6 µM, was obtained in the absence of 5% DMSO and Igepal. Similarly, V max was not affected, with comparable values of 2.5 and 1.7 relative fluorescence units/min obtained in the presence and absence, respectively, of DMSO plus Igepal, demonstrating the minimal impact of the addition of DMSO and detergent on the enzyme kinetics. Screening in nanofluidics format on the 250 HTS system requires a conversion rate of the substrate of 40% to obtain sufficient product for reliable detection. This level of conversion was reached with a concentration of enzyme of 2.25 ng/ml (data not shown). The sensitivity of the assay was evaluated using reference compounds. An IC 50 value of 0.73 µM (Fig. 6) was obtained with vanadate comparable to the one (0.48 µM) calculated in the DiFMUP assay. Similarly, an IC 50 value of 3.9 µM was obtained for compound A, close to the value (4.8 µM) of the DiFMUP assay. Therefore, sensitivity of both assays is likely to be comparable.
Screening in mobility shift format
A total of 12,648 compounds, comprising all 12,403 compounds tested in DiFMUP format, were evaluated in duplicate in 15 runs. Distribution of the low controls (no enzyme) was centered on 100% inhibition, with a standard deviation value of 1.1% comparable to the value (0.5%) obtained with the DiFMUP assay. However, the standard deviation of the high controls was high, at 20.4% (Fig. 7) , significantly higher than the value of 8.9% obtained in the DiFMUP assay. This could be explained by the difference of signal-to-background ratio throughout the runs (varying from 5 to 155) due to a percentage of conversion that varied dramatically (Fig. 8A) between individual runs. To date, we have no obvious explanation for this variability, as an aliquot of enzyme was freshly thawed for each run and the enzyme appeared to be stable in the DiFMUPbased assay. However, the assay was robust, with individual Z′ factor values ranging from 0.38 to 0.9 with an average value of 0.61 (Fig. 8B) . As a threshold for selecting positives, a value corresponding to 3 standard deviations from the low controls was selected-namely, 61% inhibition. Applying this threshold, 356 compounds were considered as positives, corresponding to a hit rate of 2.8%. Analysis of the duplicates was performed, and the correlation between duplicates (n1 and n2) obtained in 2 independent runs was fair (Fig. 9) .
Comparison of the outcomes of the screens
Only data obtained in both assays on the 12,403 common compounds were compared. Considering a threshold of 3 standard deviations from the high control as significant to define a compound as a positive, the respective cutoffs for the DiFMUP and mobility shift assay were 27% and 61% inhibition, generating, respectively, 709 and 356 positives. Considering that the 2 reference compounds evaluated in the assay, namely, vanadate and compound A, displayed similar IC 50 values in both assays and assuming therefore that the 2 assays display the same sensitivity, when the same cutoff of 61% inhibition was arbitrarily applied to both assays to select only potent inhibitors, mobility shift assay stood out in terms of number of potent positives, namely, providing 356 potent positives versus 115 for the DiFMUP-based assay. Of the 356 potent positives in the mobility shift assay, 170 (47.8%) were positive only in this format with an inhibition below 27% in the DiFMUP-based format, whereas 119 (33.4%) displayed low inhibition in the DiFMUP-based assay (between 27% and 61% inhibition), and only 67 (18.8%) were potent inhibitors in both assay formats. Conversely, a majority of the potent (>61% inhibition) positives in the DiFMUP assay were found positive in the mobility shift assay (namely, 67 of 115 or 58.3%; Fig. 10 ). Interestingly, with 1 exception, all of the most potent compounds in the DiFMUP assay (>80% inhibition) were also identified in the mobility shift assay.
Physicochemical characteristics of the 12,403 compounds common to both assays are summarized in Table 2 . Notably, the mean molecular weight was 410.5, lipophilicity (logP) 2.9, hydrogen bond acceptor 6.7, hydrogen bond donors 1.8, rotatable bonds 6.9, and topological polar surface area 88.8. Unsurprisingly, the subpopulation of compounds inactive in both assays (i/i; Table 3 ) displayed the same characteristics as the whole set. Compounds positive in DiFMUP and inactive in mobility shift assay (subpopulations w/i and p/i) were characterized by a higher average lipophilicity (6.2 and 8.7, respectively), a higher molecular weight, and a larger number of rotatable bonds. Interestingly, subpopulations of compounds active in the mobility shift assay (populations w/p, i/p, p/p) were closer to druglike properties, with mean logP values in the 4.0 to 4.3 range and a mean weight between 453 and 471. These results are displayed graphically in Figure 11 as the normalized deviations of the subpopulations' medians from the median of the total population for each of the 6 descriptors. It clearly appears that compounds positive only in the DiFMUP assay are characterized by a higher logP, a higher number of rotatable bonds, and a somewhat higher weight. Therefore, beside the subpopulation active in both assays (p/p), it appears that the mobility shift assay allowed us to identify positives distinct from the ones found with DiFMUP-based assays and displaying interesting physicochemical characteristics from a drug-likeness point of view.
CONCLUSIONS
The goal of this study was to evaluate the outcome of screening a focused phosphatase library using 2 different substrates, a generic small molecule (i.e., DiFMUP) and a specific peptide. Both assay formats proved to be comparable in terms of robustness and sensitivity to reference compounds. One issue encountered during screening in mobility shift format was the variability of the enzyme in terms of activity. As the frozen aliquots used for both assays came from the same enzyme pool and were handled similarly, it is unlikely that the variations in terms of enzyme activity could be explained by heterogeneity of the aliquots or differences in the way of handling the enzyme. The main difference between the DiFMUP and peptide-based assays is the nature of the substrate and its level of conversion, namely, 20% in the DiFMUP-based assay and nominally 40% in the mobility shift assay. It could be that at these high conversion rates, the enzyme behaves erratically or that this phenomenon is somehow linked to the technology itself. Further screening on different phosphatases will tell if this is a unique case or a general feature of this enzyme class. This variation in enzyme activity is the most likely explanation for the wide distribution of the high controls, with a standard deviation of 20% in the mobility shift assay.
However, one specific limitation of the peptide-based substrate approach is the need to identify a suitable substrate. One can either use specific peptide arrays based on known or putative sequences or generic peptide sets corresponding to known phosphorylation sites. Peptide arrays can be synthesized in house, for instance on cellulose membrane, 19 or they can be obtained from suppliers (e.g., Jerini, Berlin, Germany) under the form of microarrays or microplates either custom designed or as off-theshelf libraries. Moreover, 2 constraints are affecting the mobility shift-based methods, namely, the size (up to 20 aa) of the peptide and its net charge (between -3 and +3), both affecting the electrophoretic separation between product and substrate.
On the other hand, phosphatase assays using a generic fluorescent substrate are easy to establish and automate. Setting up an assay requires determining only the K m value for the substrate and the kinetics of the reaction as a function of both time 
FIG. 11.
Physicochemical characteristics of compound subpopulations, classified by activity, relative to the entire population. The plot illustrates the deviations of the subpopulations' medians from the median of the total population for each of the 6 descriptors, normalized by half the respective interquantile (15%-85%) distances. i = inactive; w = weak; p = potent in DiFMUP (left) versus mobility shift assay (right); HBD = hydrogen bond donor; HBA = hydrogen bond acceptor; logP = lipophilicity; tPSA = topological polar surface area; nRot = number of rotatable bonds.
and enzyme concentration. Similarly, automation is straightforward, allowing rapid target hopping, as the differences among assays are the enzyme itself and the concentration of substrate used, close to its K m value. Moreover, the cost of fluorescent substrates such as DiFMUP is low, about 0.5 cents/well. However, fluorescence-based methods are sensitive to quenching or fluorogenic compounds, especially when substrate concentrations are in the low nanomolar range. 20, 21 In the specific case of DiFMUP-based assays, as the substrate is used in the micromolar range, compound interference is not such a problem, whereas the mobility shift assay technology bypasses this problem by separating substrate and product peaks, with the fluorescent compounds appearing as single peaks. 21 Still, the most striking feature of the mobility shift assay was the identification of compounds that are different from the ones identified in a classical DiFMUP-based assay, notably displaying physicochemical characteristics closer to druglike properties. 22 A similar observation was previously reported for kinases, in which different screening readouts generated different positives. 23 Therefore, the main conclusion of this study is that for future phosphatase screens, it is worthwhile to invest time and effort in developing substrate specific tools to discover novel chemical entities as starting points for chemistry efforts.
